Company: PSTV
Filing Date: 2025-03-14
Form Type: PRE 14A
Source: 0001140361-25-008857
Chunk: 33

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-14
Form: PRE 14A
Chunk 33
---
 ensure compliance with Nasdaq Listing Rule 5635(d), which provides that stockholder approval is required prior to the issuance of securities in a transaction, other than a public offering, involving the sale, issuance or potential issuance by the Company of Common Stock (or securities convertible into or exercisable for Common Stock), which equals 20% or more of the Common Stock or 20% or more of the voting power outstanding before the issuance, at a price less than the lower of: (i) the closing price immediately preceding the signing of the binding agreement, or (ii) the average closing price of the Common Stock for the five trading days immediately preceding the signing of the binding agreement for the transaction.

#### Potential Effects of Approval of this Proposal
If approved, this Proposal No. 4 could result in the issuance of shares of Common Stock upon the exercise of the May 2024 Warrants subject to their respective beneficial ownership limitations during a period not initially contemplated upon initial issue.

Upon issuance of shares of Common Stock upon the exercise of the May 2024 Warrants, there would be a greater number of shares of our Common Stock eligible for sale in the public markets. Any such sales, or the anticipation of the possibility of such sales, represents an overhang on the market and could depress the market price of our Common Stock. Finally, the reservation of the shares underlying the May 2024 Warrants precludes the Company from issuing such shares for other purposes including equity financings and we may be unable to raise additional capital as a result.

**Potential Effects of Non-Approval of this Proposal**

The Company is not seeking the approval of stockholders to authorize its entry into the SPEA, as the Company has already done so and the relevant documents are already binding obligations of the Company. The failure of stockholders to approve this proposal will not negate the existing terms of the transactions or the relevant documents, which will remain binding on the Company.

Failure to obtain stockholder approval may materially adversely affect the Company’s future ability to raise equity or debt capital from third parties on attractive terms, if at all, and also risks significantly impairing the operations, assets and ongoing viability of the Company.

Additionally, if approval is not obtained at the Special Meeting, the Company will be obligated to continue to seek stockholder approval at least three times each year until stockholder approval is obtained.

#### Interests of Officers and Directors this Proposal
Our executive officers and directors who hold May 2024 Warrants have an interest in this Proposal No. 4 by virtue